Murray, RM, Morrison, PD, Henquet, C, Di Forti, M. Cannabis, the mind and society: the hash realities. Nat Rev Neurosci
2007; 8: 885–95.
Grech, A, Van Os, J, Jones, PB, Lewis, SW, Murray, RM. Cannabis use and outcome of recent onset psychosis. Eur Psychiatry
2005; 20: 349–53.
Caspari, D. Cannabis and schizophrenia: results of a follow-up study. Eur Arch Psychiatry Clin Neurosci
1999; 249: 45–9.
Linszen, DH, Dingemans, PM, Lenior, ME. Cannabis abuse and the course of recent-onset schizophrenic disorders. Arch Gen Psychiatry
1994; 51: 273–9.
Compton, MT, Furman, AC, Kaslow, NJ. Lower negative symptom scores among cannabis-dependent patients with schizophrenia-spectrum disorders: preliminary evidence from an African American first-episode sample. Schizophr Res
2004; 71: 61–4.
Spencer, C, Castle, D, Michie, PT. Motivations that maintain substance use among individuals with psychotic disorders. Schizophr Bull
2002; 28: 233–47.
Ferdinand, RF, Sondeijker, F, van der Ende, J, Selten, JP, Huizink, A, Verhulst, FC. Cannabis use predicts future psychotic symptoms, and vice versa. Addiction
2005; 100: 612–8.
Henquet, C, Krabbendam, L, Spauwen, J, Kaplan, C, Lieb, R, Wittchen, HU, et al. Prospective cohort study of cannabis use, predisposition for psychosis, and psychotic symptoms in young people. BMJ
2005; 330: 11–5.
Stefanis, NC, Delespaul, P, Henquet, C, Bakoula, C, Stefanis, CN, Van Os, J. Early adolescent cannabis exposure and positive and negative dimensions of psychosis. Addiction
2004; 99: 1333–41.
McGuffin, P, Farmer, A, Harvey, I. A polydiagnostic application of operational criteria in studies of psychotic illness: development and reliability of the OPCRIT system. Arch Gen Psychiatry
1991; 48: 764–70.
Spitzer, RL, Endicott, J, Robins, E. Research diagnostic criteria: rationale and reliability. Arch Gen Psychiatry
1978; 35: 773–82.
Kay, SR, Fiszbein, A, Opler, LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull
1987; 13: 261–76.
Myin-Germeys, I, van Os, J, Schwartz, JE, Stone, AA, Delespaul, PA. Emotional reactivity to daily life stress in psychosis. Arch Gen Psychiatry
2001; 58: s1137–44.
Myin-Germeys, I, Krabbendam, L, Jolles, J, Delespaul, PA, van Os, J. Are cognitive impairments associated with sensitivity to stress in schizophrenia? An experience sampling study. Am J Psychiatry
2002; 159: 443–9.
Delespaul, PAEG. Empirical studies in ESM reliability and validity. In Assessing Schizophrenia in Daily Life: The Experience Sampling Method. (ed. de Vries, MW): 107. Maastricht University Press, 1995.
Myin-Germeys, I, Marcelis, M, Krabbendam, L, Delespaul, P, van Os, J. Subtle fluctuations in psychotic phenomena as functional states of abnormal dopamine reactivity in individuals at risk. Biol Psychiatry
2005; 58: 105–10.
Van Winkel, R, Henquet, C, Rosa, A, Papiol, S, Fananas, L, De Hert, M, et al. Evidence that the COMT(Val158Met) polymorphism moderates sensitivity to stress in psychosis: an experience-sampling study. Am J Med Genet B Neuropsychiatr Genet
2008; 147: 10–7.
Delespaul, P, deVries, M, van Os, J. Determinants of occurrence and recovery from hallucinations in daily life. Soc Psychiatry Psychiatr Epidemiol
2002; 37: 97–104.
Van Os, J, Bak, M, Hanssen, M, Bijl, RV, de Graaf, R, Verdoux, H. Cannabis use and psychosis: a longitudinal population-based study. Am J Epidemiol
2002; 156: 319–27.
D'Souza, DC, Abi-Saab, WM, Madonick, S, Forselius-Bielen, K, Doersch, A, Braley, G, et al. Delta-9-tetrahydrocannabinol effects in schizophrenia: implications for cognition, psychosis, and addiction. Biol Psychiatry
2005; 57: 594–608.
Romme, MA, Honig, A, Noorthoorn, EO, Escher, AD. Coping with hearing voices: an emancipatory approach. Br J Psychiatry
1992; 161: 99–103.
Myin-Germeys, I, Delespaul, P, van Os, J. Behavioural sensitization to daily life stress in psychosis. Psychol Med
2005; 35: 733–41.
Arseneault, L, Cannon, M, Poulton, R, Murray, R, Caspi, A, Moffitt, TE. Cannabis use in adolescence and risk for adult psychosis: longitudinal prospective study. BMJ
2002; 325: 1212–3.
Thewissen, V, Bentall, RP, Lecomte, T, van Os, J, Myin-Germeys, I. Fluctuations in self-esteem and paranoia in the context of daily life. J Abnorm Psychol
2008; 117: 143–53.
Giuffrida, A, Leweke, FM, Gerth, CW, Schreiber, D, Koethe, D, Faulhaber, J, et al. Cerebrospinal anandamide levels are elevated in acute schizophrenia and are inversely correlated with psychotic symptoms. Neuropsychopharmacology
2004; 29: 2108–14.
Wilson, RI, Nicoll, RA. Endogenous cannabinoids mediate retrograde signalling at hippocampal synapses. Nature
2001; 410: 588–92.
Elphick, MR, Egertova, M. The neurobiology and evolution of cannabinoid signalling. Philos Trans R Soc Lond B Biol Sci
2001; 356: 381–408.
Chevaleyre, V, Takahashi, KA, Castillo, PE. Endocannabinoid-mediated synaptic plasticity in the CNS. Ann Rev Neurosci
2006; 29: 37–76.
Leweke, FM, Koethe, D. Cannabis and psychiatric disorders: it is not only addiction. Addict Biol
2008; 13: 264–75.
Cheer, JF, Wassum, KM, Heien, ML, Phillips, PE, Wightman, RM. Cannabinoids enhance subsecond dopamine release in the nucleus accumbens of awake rats. J Neurosci
2004; 24: 4393–400.
Riegel, AC, Lupica, CR. Independent presynaptic and postsynaptic mechanisms regulate endocannabinoid signaling at multiple synapses in the ventral tegmental area. J Neurosci
2004; 24: 11070–8.
Kapur, S, Mizrahi, R, Li, M. From dopamine to salience to psychosis: linking biology, pharmacology and phenomenology of psychosis. Schizophr Res
2005; 79: 59–68.
Bentall, RP, Kinderman, P, Kaney, S. The self, attributional processes and abnormal beliefs: towards a model of persecutory delusions. Behav Res Ther
1994; 32: 331–41.
Bossong, MG, van Berckel, BN, Boellaard, R, Zuurman, L, Schuit, RC, Windhorst, AD, et al. Delta 9-tetrahydrocannabinol induces dopamine release in the human striatum. Neuropsychopharmacology
2009; 34: 759–66.
Stokes, PR, Mehta, MA, Curran, HV, Breen, G, Grasby, PM. Can recreational doses of THC produce significant dopamine release in the human striatum?
2009; 48: 186–90.
Henquet, C, Di Forti, M, Morrison, P, Kuepper, R, Murray, RM. Gene-environment interplay between cannabis and psychosis. Schizophr Bull
2008; 34: 1111–21.
Arseneault, L, Cannon, M, Witton, J, Murray, RM. Causal association between cannabis and psychosis: examination of the evidence. Br J Psychiatry
2004; 184: 110–7.
Houston, JE, Murphy, J, Adamson, G, Stringer, M, Shevlin, M. Childhood sexual abuse, early cannabis use, and psychosis: testing an interaction model based on the National Comorbidity Survey. Schizophr Bull
2008; 34: 580–5.
Harley, M, Kelleher, I, Clarke, M, Lynch, F, Arseneault, L, Connor, D, et al. Cannabis use and childhood trauma interact additively to increase the risk of psychotic symptoms in adolescence. Psychol Med
2009; 9: 1–8.
Caspi, A, Moffitt, TE, Cannon, M, McClay, J, Murray, R, Harrington, H, et al. Moderation of the effect of adolescent-onset cannabis use on adult psychosis by a functional polymorphism in the catechol-O-methyltransferase gene: longitudinal evidence of a gene×environment interaction. Biol Psychiatry
2005; 57: 1117–27.
Henquet, C, Rosa, A, Krabbendam, L, Papiol, S, Fananas, L, Drukker, M, et al. An experimental study of catechol-O-methyltransferase Val(158)Met moderation of delta-9-tetrahydrocannabinol-induced effects on psychosis and cognition. Neuropsychopharmacology
2006; 31: 2748–57.
Jacobs, N, Nicolson, NA, Derom, C, Delespaul, P, van Os, J, Myin-Germeys, I. Electronic monitoring of salivary cortisol sampling compliance in daily life. Life Sci
2005; 76: 2431–43.
Di Forti, M, Morgan, C, Dazzan, P, Pariante, C, Mondelli, V, Marques, TR, et al. High-potency cannabis and the risk of psychosis. Br J Psychiatry
2009; 195: 488–91.
Morgan, CJA, Curran, HV. Effects of cannabidiol on schizophrenia-like symptoms in people who use cannabis. Br J Psychiatry
2008; 192: 306–7.
Bhattacharyya, S, Morrison, PD, Fusar-Poli, P, Martin-Santos, R, Borgwardt, S, Winton-Brown, T, et al. Opposite effects of delta-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology. Neuropsychopharmacology
2010; 35: 764–74.
D'Souza, DC, Ranganathan, M, Braley, G, Gueorguieva, R, Zimolo, Z, Cooper, T, et al. Blunted psychotomimetic and amnestic effects of delta-9-tetrahydrocannabinol in frequent users of cannabis. Neuropsychopharmacology
2008; 33: 2505–16.
Barrowclough, C, Haddock, G, Tarrier, N, Lewis, SW, Moring, J, O'Brien, R, et al. Randomized controlled trial of motivational interviewing, cognitive behavior therapy, and family intervention for patients with comorbid schizophrenia and substance use disorders. Am J Psychiatry
2001; 158: 1706–13.